Bay & Deveaux Streets
Industry: Diagnostic Substances
Full Time Employees:
|Dr. Paul Averback M.D., DABP||Founder, Chairman, Chief Exec. Officer and Pres||75k||N/A||66|
|Mr. Erik Danielsen||Chief Financial Officer||250k||N/A||54|
|Mr. Randall J. Lanham Esq.||Gen. Counsel, Sec. and Director||185k||N/A||53|
|Dr. Judith Fitzpatrick Ph.D.||Exec.||N/A||N/A||68|
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. It markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. The company also offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimers disease. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in Phase III clinical trials for the treatment of enlarged prostate or benign prostatic hyperplasia, as well as is in Phase II clinical trial for low grade localized prostate cancer. The company markets its products in Canada, the United States, Europe, and internationally. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, The Bahamas.
Nymox Pharmaceutical Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.